Biotie Therapies in Turku, Finland, has announced a $2 million investment from the Michael J. Fox Foundation for Parkinson's Research to investigate the safety and tolerability of Alzheimer's drug SYN120 in Parkinson's disease patients with dementia.
The grant will fund an eighty-patient double-blind placebo-controlled trial in patients with Parkinson's disease dementia. The sixteen-week trial, which aims to establish the efficacy of SYN120 on cognition, will be conducted by the Parkinson Study Group at ten sites in the U.S. specializing in cognitive dysfunction in Parkinson's disease.
"There is an urgent need to find safe and effective treatments for Parkinson's patients suffering from impaired cognition," said Biotie CEO Timo Veromaa. "We look forward to collaborating with MJFF and the Parkinson Study Group to advance SYN120 into a phase two trial later this year. This grant provides a great opportunity to further characterize the potential of this drug candidate."